Review article: Gastric pH - The most relevant predictor of benefit in reflux disease?

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 5, 2004, Pages 19-26

  Armstrong, D ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; ELECTRODE; ESOPHAGUS INJURY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; INDIVIDUAL BASED POPULATION MODEL; META ANALYSIS; PH MEASUREMENT; PREDICTION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; STOMACH PH; SYSTEMATIC REVIEW; WOUND HEALING;

EID: 7044232914     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02140.x     Document Type: Conference Paper

References (47)

1. Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastro-oesophageal reflux. Gut 1988; 29: 1020-8.
2. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999: 44(Suppl. 2): S1-6.
3. Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101: 1149-58.
4. Bell NJ. Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
5. Weusten BL, Akkermans LM, vanBerge-Henegouwen GP, Smout AP. Spatiotemporal characteristics of physiological gastroesophageal reflux. Am J Physiol 1994: 266: G357-62.
6. Armstrong D, Emde C, Blum AL. Long-term ambulatory gastric pH-metry: easy to do but difficult to analyze. Eur J Gastroenterol Hepatol 1989: 1: 167-74.
7. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
8. Howden CW. Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4: 25-33.
9. Cilluffo T, Armstrong D, Castiglione F, et al. Reproducibility of ambulatory gastric pH recordings in corpus and antrum: effect of food, time and electrode position. Scand J Gastroenterol 1990: 25: 1076-83.
10. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994; 106: 60-4.
11. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2-RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
12. Armstrong D, Bair D, James C, Tanser L, Escobedo S, Nevin K. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment Pharmacol Ther 2003: 18: 705-12.
13. el-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995: 109: 681-91.
14. Verdú EF, Armstrong D, Fraser R, et al. Helicobacter pylori infection interacts with acid inhibition by omeprazole. Gut 1995; 36: 539-43.
15. Verdú EF, Armstrong D, Idström J, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995; 37: 743-8.
16. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
17. Emde C, Garner A, Blum AL. Technical aspects of intraluminal pH-metry in man: current status and recommendations. Gut 1987; 88: 1177-88.
18. Duroux P, Emde C, Bauerfeind P, et al. The ISFET pH electrode: a new sensor for long-term ambulatory pH-metry. Gut 1991; 32: 240-5.
19. Sharma BK, Walt RP, Pounder RE, Gomes MD, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24-hour decrease of intragastric acidity. Gut 1984; 25: 957-64.
20. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7.
21. Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg versus omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 954-8.
22. Wilder-Smith C, Röhss K, Lundin C, et al. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 2000; 118: A22(Abstract).
23. Wilder-Smith C, Claar-Nilsson C, Hasselgren G, et al. Esomeprazole provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD. Am J Gastroenterol 2001: 96(Suppl.): 45.
24. Wilder-Smith C, Röhss K, Claar-Nilsson C, et al. Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg. Gut 2000; 47(Suppl. III): A63(Abstract).
25. Wilder-Smith C, Röhss K, Claar-Nilsson C, et al. Esomeprazole 40 mg provides faster and more effective acid control than lansoprazole 30 mg in patients with symptoms of gastroesophageal reflux disease. Gastroenterology 2002; 122(Suppl. I): A2OO(Abstract).
26. Thomson ABR, Claar-Nilsson C, Hasselgren G, et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration. Gut 2000; 47(Suppl. III): A63(Abstract).
27. Wilder-Smith C, Röhss K, Claar-Nilsson C, et al. Esomeprazole 20 mg provides faster and more effective acid control than lansoprazole 15 mg. Gut 2000; 47(Suppl. III): A62-3 (Abstract).
28. Miner PB Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
29. Wilder-Smith C, Lind T, Lundin C, et al. Comparison of esomeprazole (20, 40, 80 mg) versus lansoprazole (15, 30, 60 mg) on intragastric pH in healthy subjects. Gastroenterology 2003; 124: A444(Abstract).
30. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 1507-14.
31. Chiba N, de Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
32. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1729-36.
33. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15: 1563-9.
34. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
35. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
36. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
37. Labenz J, Keeling N, Eklund S, et al. A comparison of esomeprazole 40 mg once-daily and pantoprazole 40 mg once-daily for the healing of reflux oesophagitis. Gut 2003; 52(Suppl. VI): A241(Abstract).
38. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27-34.
39. Vakil NB, Shaker R, Hwang C, et al. The new proton pump inhibitor esomeprazole is effective as maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927-35.
40. Lauritsen K, Devière J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17: 333-41.
41. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.
42. Carlsson R, Galmiche J-P, Dent J, Lundell L, Frison L. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1997; 10: 119-24.
43. Armstrong D, Paré P, Pericak D, Pyzyk M, the Canadian Pantoprazole GERD Study Group. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96: 2849-57.
44. Bate CM, Green JR, Axon AT, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 1997; 11: 755-63.
45. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of non-erosive gastroesophageal reflux disease. Arch Intern Med 2000; 160: 1803-9.
46. Clouse RE, Richter RE, Heading RC. Jassens J, Wilson JA. Functional esophageal disorders. Gut 1999; 45(Suppl. II): II31-6.
47. Fass R, Tougas G. Functional heartburn: the stimulus, the pain and the brain. Gut 2002; 51: 885-92.